Publication Instructions:

BMT CTN Protocol 0403
- Primary and Ancillary Studies –

The requirements below are for publications and presentations made pursuant to the primary BMT CTN Study 0403. For 0403 ancillary studies please contact the email below.

Acknowledgment Requirements:

For all Publications, Reports, Presentations, Symposiums, etc.

"Support for this study was provided by grant #U10HL069294 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute along with contributions by Immunex Corporation, a wholly owned subsidiary of Amgen Inc. The content is solely the responsibility of the authors and does not necessarily represent the official views of the above mentioned parties."

The following language should be inserted in the acknowledgements for all BMT CTN Studies that utilize CIBMTR data:
The CIBMTR registry is supported primarily by the U24-CA76518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases and from HHSH234200637015C (HRSA/DHHS) to the Center for International Blood and Marrow Transplant Research.

Review Requirements:

For all Publications, Reports, Presentations, Symposiums, etc.

BMT CTN: Abstracts, presentations, and proposed publications relating to data obtained from BMT CTN protocols or to activities of BMT CTN Committees or Protocol Teams are to be submitted to the DCC for review.

Immunex / Amgen: Prior to submission for publication or presentation, Amgen shall be provided (1) **30 days** to review and to request, in writing, to remove all confidential information from a **manuscript** and (2) **15 day** to review and to request, in writing, to remove all confidential information from any **poster presentation, abstract or other written or oral material** which describes the results of the study. These restrictions do not apply to written or oral material displayed or transmitted within the BMT CTN, among the PI, the investigators, and their staff as part of the performance of the protocol, and to cognizant federal agencies or departments as part of the reporting requirements of the protocol.

Questions regarding the above requirements may be directed to the Data Coordinating Center, NMDP Contracts & Procurement Department at NMDP_BMTCTN_Pub@nmdp.org.